Enzymes of carnitine biosynthesis

The enzymes of carnitine biosynthesis represent a multi-step metabolic pathway essential for the de novo synthesis of L-carnitine from lysine and methionine. This pathway involves four primary enzymes: 6-N-trimethyllysine dioxygenase (TMLHE), 3-hydroxy-6-N-trimethyllysine aldolase, 4-trimethylammoniobutyraldehyde dehydrogenase (ALDH9A1), and gamma-butyrobetaine dioxygenase (BBOX1). L-carnitine plays a vital role in energy metabolism by facilitating the transport of long-chain fatty acids across the inner mitochondrial membrane for beta-oxidation. The final enzyme in the pathway, BBOX1, is a significant therapeutic target; its inhibition reduces carnitine levels and shifts cellular metabolism toward glucose oxidation, which requires less oxygen per ATP produced. This metabolic shift is clinically exploited by drugs like meldonium to treat ischemic heart disease and other cardiovascular conditions. Beyond cardiology, these enzymes are under investigation for their roles in cancer metabolism, as certain tumors rely on carnitine-mediated fatty acid oxidation for survival and proliferation. Deficiencies in these enzymes, particularly TMLHE, have also been linked to neurodevelopmental disorders such as autism.

Other names

Carnitine biosynthetic pathwayL-carnitine biosynthesis enzymesTrimethyllysine to carnitine pathway

Inhibition of gamma-butyrobetaine dioxygenase (BBOX1) to reduce endogenous carnitine levels, thereby shifting energy metabolism from fatty acid oxidation to glucose oxidation to protect tissues under hypoxic conditions.